serotonin & norepinephrine reuptake inhibitor (SNRI, dual-acting reuptake inhibitor)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4]

Indications

* modestly better than placebo for treating depression, OCD, anxiety in children & adolescents[2]

* SNRI benefit for anxiety in children limited to clinician- reported, not child- or parent-reported symptoms[3]

* patients with depression & anhedonia, abulia, fatigue, or psychomotor retardation receive treatment with an SNRI rather than SSRI[4]

Mechanism of action

More general terms

More specific terms

Additional terms

References

  1. ↑ Prescriber's Letter 11(9): 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200901&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. ↑ 2.0 2.1 2.2 Locher C, Koechlin H, Zion SR et al Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents. A Systematic Review and Meta-analysis. JAMA Psychiatry. Published online August 30, 2017. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28854296 <Internet> http://jamanetwork.com/journals/jamapsychiatry/fullarticle/2652447
    Merry SN, Hetrick SE, Stasiak K. Effectiveness and Safety of Antidepressants for Children and Adolescents. Implications for Clinical Practice. JAMA Psychiatry. Published online August 30, 2017. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28854300 <Internet> http://jamanetwork.com/journals/jamapsychiatry/fullarticle/2652446
  3. ↑ 3.0 3.1 Wang Z, Whiteside SPH, Sim L et al Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders. A Systematic Review and Meta-analysis. JAMA Pediatr. Published online August 31, 2017. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28859190 <Internet> http://jamanetwork.com/journals/jamapediatrics/fullarticle/2650801
    Asarnow JR, Rozenman MS, Carlson GA Medication and Cognitive Behavioral Therapy for Pediatric Anxiety Disorders. No Need for Anxiety in Treating Anxiety. JAMA Pediatr. Published online August 31, 2017. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28859188 <Internet> http://jamanetwork.com/journals/jamapediatrics/fullarticle/2650800
  4. ↑ 4.0 4.1 Bennabi D, Charpeaud T, Yrondi A et al Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry. 2019 Aug 28;19(1):262. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31455302 PMCID: PMC6712810
Retrieved from "https://aaushi.info/w/index.php?title=A313&oldid=1147418"